Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases.

CTP-692

A promising first-in-class approach to broaden the scope of treating schizophrenia

CTP-543

A drug candidate for alopecia areata, a disease with no currently-approved treatments

LATEST NEWS

Dec 02, 2019
Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia

Nov 12, 2019
Concert Pharmaceuticals to Present at Upcoming Investor Conferences

© 2019 Concert Pharmaceuticals. All rights reserved.
HOME | SITEMAP | CONTACT | TERMS OF USE | PRIVACY POLICY
Back to Top